summa tirzepatide Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide

Kidney Disease Progression: Recent data also supports its role in reducing the risk of kidney disease progression and serious heart-related problems in adults with type 2 diabetes and chronic kidney disease

It requires two copper ions at its active site to catalyse the conversion of tyrosine to DOPA and then to DOPAquinone the precursor of eumelanin

CNS Drugs 33, 143160

Study selection The criteria for including studies in this meta-analysis were as follows: (1) (i) randomized controlled trials (RCTs) comparing different AOMs with placebo, including glucagon-like peptide 1 receptor agonist (GLP-1 RA), dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs, GLP-1 and glucagon receptor (GCGR) dual-agonist, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and bimagrumab